Nanomix, Emeryville, Calif, has submitted an emergency use authorization request to the FDA for the eLab covid-19 rapid antigen test. The assay runs on the portable Nanomix eLab analyzer, which provides results in just 15 minutes and can be used in a wide range of settings, including hospitals, nursing homes, assisted living facilities, urgent care centers, and emergency medical care.
The Nanomix eLab platform and covid-19 rapid antigen test will enable medical professionals, emergency workers, and employers to test individuals for antigens that indicate covid-19 infection. The assay uses a nasal swab sample that can be self-administered, and is designed to complement existing test methods by expanding access to rapid, laboratory-quality results outside of hospital facilities.
“While the global healthcare community has made tremendous progress in covid-19 testing, there is still significant need for rapid, accurate, and affordable testing that can be conducted outside of laboratory settings,” says David Ludvigson, president and CEO of Nanomix. “By completing this EUA filing, we are one step closer to making our antigen test available to help address this remaining gap.”
Nanomix previously validated and made available a rapid test for IgG and IgM antibodies that also runs on the eLab analyzer, and indicates past exposure to the SARS-CoV-2 virus.
Nanomix developed both the covid-19 antigen and antibody assays in part with funding from BARDA.
For more information, visit www.nano.com.